首页> 外文OA文献 >Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes
【2h】

Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes

机译:使用靶向Bcl-2和Bcl-xL基因的双特异性反义寡核苷酸诱导人前列腺癌LNCaP细胞凋亡并增强化学敏感性

摘要

OBJECTIVE: To determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumour progression in many malignancies, including prostate cancer. MATERIALS AND METHODS: Inhibition of Bcl-2 and Bcl-xL expression by the bispecific ASO was evaluated using real-time reverse transcription-polymerase chain reaction and Western blotting, while growth inhibition and induction of apoptosis were analysed by a crystal violet assay, flow cytometry and Western blotting of apoptosis-relevant proteins. The effect of combined treatment with bispecific ASO and chemotherapy or small-interference RNA (siRNA) targeting the clusterin gene was also investigated. RESULTS: Bispecific ASO reduced Bcl-2 and Bcl-xL expression in LNCaP cells in a dose-dependent manner. There was cell growth inhibition, increases in the sub-G0-G1 fraction, and cleavage of caspase-3 and poly(ADP-Ribose) polymerase proteins in LNCaP cells after bispecific ASO treatment. Interestingly, Bcl-2/Bcl-xL bispecific ASO treatment also resulted in the down-regulation of Mcl-1 and up-regulation of Bax. The sensitivity of LNCaP cells to mitoxantrone, docetaxel or paclitaxel was significantly increased, reducing the 50% inhibitory concentration by 45%, 80% or 90%, respectively. Furthermore, the apoptotic induction by Bcl-2/Bcl-xL bispecific ASO was synergistically enhanced by siRNA-mediated inhibition of clusterin, a cytoprotective chaperone that interacts with and inhibits activated Bax. CONCLUSIONS: These findings support the concept of the targeted suppression of Bcl-2 anti-apoptotic family members using multitarget inhibition strategies for prostate cancer, through the effective induction of apoptosis.
机译:目的:确定专门设计的双特异性(Bcl-2 / Bcl-xL)反义寡核苷酸(ASO)是否能诱导人前列腺癌LNCaP细胞凋亡并增强其化学敏感性,因为Bcl-2和Bcl-xL都是与抗凋亡基因相关的在包括前列腺癌在内的许多恶性肿瘤中具有治疗抗性和肿瘤进展。材料与方法:采用实时逆转录-聚合酶链反应和蛋白质印迹法评估了双特异性ASO对Bcl-2和Bcl-xL表达的抑制作用,同时通过结晶紫分析法分析了生长抑制和凋亡诱导。细胞凋亡和凋亡相关蛋白的蛋白质印迹。还研究了双特异性ASO与化学疗法或靶向簇蛋白基因的小干扰RNA(siRNA)联合治疗的效果。结果:双特异性ASO以剂量依赖性方式降低了LNCaP细胞中Bcl-2和Bcl-xL的表达。在双特异性ASO处理后,LNCaP细胞中存在细胞生长抑制,sub-G0-G1部分增加以及caspase-3和聚(ADP-核糖)聚合酶蛋白的裂解。有趣的是,Bcl-2 / Bcl-xL双特异性ASO处理也导致Mcl-1的下调和Bax的上调。 LNCaP细胞对米托蒽醌,多西紫杉醇或紫杉醇的敏感性显着提高,分别将50%抑制浓度降低了45%,80%或90%。此外,Bcl-2 / Bcl-xL双特异性ASO的凋亡诱导作用通过siRNA介导的簇蛋白(一种与细胞相互作用并抑制活化的Bax的细胞保护性伴侣蛋白)的抑制作用而协同增强。结论:这些发现支持通过有效诱导凋亡,采用多靶点抑制策略对前列腺癌Bcl-2抗凋亡家族成员进行靶向抑制的概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号